+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Postoperative Ileus - Pipeline Review, H2 2019

  • ID: 4901296
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 40 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ChironWells GmbH
  • Leading BioSciences Inc
  • Orexa BV
  • RaQualia Pharma Inc
  • Yuhan Corp
  • MORE
Postoperative Ileus - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Postoperative Ileus - Pipeline Review, H2 2019, provides an overview of the Postoperative Ileus (Gastrointestinal) pipeline landscape.

Post-operative ileus describes as an arrest in intestinal motility following surgery. Symptoms include abdominal cramping, appetite loss, feeling of fullness, constipation, inability to pass gas, stomach swelling, nausea and vomiting.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Postoperative Ileus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Postoperative Ileus (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Postoperative Ileus (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Postoperative Ileus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1 and 1 respectively.

Postoperative Ileus (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Postoperative Ileus (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Postoperative Ileus (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Postoperative Ileus (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Postoperative Ileus (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Postoperative Ileus (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Postoperative Ileus (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Postoperative Ileus (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ChironWells GmbH
  • Leading BioSciences Inc
  • Orexa BV
  • RaQualia Pharma Inc
  • Yuhan Corp
  • MORE
Introduction
Report Coverage
Postoperative Ileus - Overview
Postoperative Ileus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Postoperative Ileus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Postoperative Ileus - Companies Involved in Therapeutics Development
ChironWells GmbH
Leading BioSciences Inc
Orexa BV
RaQualia Pharma Inc
Takeda Pharmaceutical Co Ltd
Yuhan Corp
Postoperative Ileus - Drug Profiles
Postoperative Ileus - Dormant Projects
Postoperative Ileus - Discontinued Products
Postoperative Ileus - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Postoperative Ileus, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Postoperative Ileus - Pipeline by ChironWells GmbH, H2 2019
Postoperative Ileus - Pipeline by Leading BioSciences Inc, H2 2019
Postoperative Ileus - Pipeline by Orexa BV, H2 2019
Postoperative Ileus - Pipeline by RaQualia Pharma Inc, H2 2019
Postoperative Ileus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Postoperative Ileus - Pipeline by Yuhan Corp, H2 2019
Postoperative Ileus - Dormant Projects, H2 2019
Postoperative Ileus - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Postoperative Ileus, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ChironWells GmbH
  • Leading BioSciences Inc
  • Orexa BV
  • RaQualia Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll